The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
Open Access
- 1 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (15), 6387-6395
- https://doi.org/10.1158/0008-5472.can-08-0538
Abstract
Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or acquired tumor resistance. Recent clinical evidence indicates that loss of expression of HER4 is an independent marker for tamoxifen resistance. In direct corroboration with clinical observations, suppression of HER4 expression in the tamoxifen-sensitive MCF-7 and T47D breast tumor cell lines resulted in resistance to tamoxifen-induced apoptosis. Furthermore, HER4 expression was lost in three independent MCF-7 models of acquired tamoxifen resistance. The HER4 intracellular domain (4ICD) is an independently signaling nuclear protein that functions as a potent ERα coactivator. In addition, mitochondrial 4ICD functions as a proapoptotic BH3-only protein. Tamoxifen disrupts an estrogen-driven interaction between ERα and 4ICD while promoting mitochondrial accumulation of the 4ICD BH3-only protein. BCL-2 inhibition of tamoxifen-induced apoptosis and tamoxifen activation of BAK, independent of BAX, further supports a role for 4ICD during tamoxifen-induced apoptosis. Finally, reintroduction of HER4, but not HER4 with a mutated BH3 domain, restores tamoxifen sensitivity to tamoxifen-resistant TamR cells in a xenograft model. Clinically, breast cancer patients with tumor expression of nuclear 4ICD responded to tamoxifen therapy with no clinical failures reported after 14 years of follow-up, whereas 20% of patients lacking nuclear 4ICD expression succumbed to their disease within 10 years of diagnosis. Our identification of the HER4/4ICD BH3-only protein as a critical mediator of tamoxifen action provides a clinically important role for 4ICD in human cancer and reveals a potential tumor marker to predict patient response to tamoxifen therapy. [Cancer Res 2008;68(15):6387–95]Keywords
Other Versions
This publication has 40 references indexed in Scilit:
- Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrantBreast Cancer Research and Treatment, 2008
- Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domainsOncogene, 2007
- The Intracellular Domain of ErbB4 Induces Differentiation of Mammary Epithelial CellsMolecular Biology of the Cell, 2006
- Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancerEndocrine-Related Cancer, 2005
- Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cellsApoptosis, 2005
- Presenilin-dependent γ-Secretase Processing Regulates Multiple ERBB4/HER4 ActivitiesPublished by Elsevier BV ,2005
- Impaired differentiation and lactational failure ofErbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5Development, 2003
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- A novel splice variant ofHER2 with increased transformation activityMolecular Carcinogenesis, 1998
- Use of Ranks in One-Criterion Variance AnalysisJournal of the American Statistical Association, 1952